Oxbryta was supposed to help. Developed to treat sickle cell disease—a painful, debilitating blood disorder—the drug was marketed as a breakthrough that could reduce complications and improve quality of life. Instead, patients who trusted Oxbryta experienced the opposite: increased vaso-occlusive crises, more frequent hospitalizations, and in some cases, death. In September 2024, the FDA issued an urgent alert, and Pfizer voluntarily withdrew the drug from markets worldwide.

What Happened with Oxbryta

Oxbryta (voxelotor) was approved to treat sickle cell disease by increasing hemoglobin oxygen affinity—essentially helping red blood cells carry more oxygen. But postmarketing surveillance revealed a troubling pattern: patients taking Oxbryta were experiencing higher rates of vaso-occlusive crises, the excruciatingly painful episodes that are the hallmark of sickle cell disease. Hospitalizations increased. Some patients suffered strokes. Others died.

Pfizer’s own assessment concluded that the benefits of Oxbryta did not outweigh the risks. The company pulled all lots from worldwide markets. But for patients who had already been taking the drug—many of whom had few other treatment options—the damage was already done.

Who Is Affected

Sickle cell disease patients who took Oxbryta between its approval and the September 2024 recall may be eligible to pursue claims. This includes individuals who experienced increased frequency or severity of vaso-occlusive crises while on the medication, patients who were hospitalized due to complications while taking Oxbryta, anyone who suffered a stroke or other serious adverse event, and families of patients who died while taking or shortly after taking the drug.

Compensation Available

Oxbryta injury claims may seek compensation for medical costs related to hospitalizations and emergency treatment, pain and suffering from worsened sickle cell crises, costs of stroke treatment and rehabilitation, wrongful death damages for families who lost loved ones, lost wages and reduced quality of life, and future medical care needs resulting from drug-related injuries. A federal jury trial date has been set for August 2027, and a settlement agreement was announced in October 2025.

Living with sickle cell disease is already a daily struggle. Patients who placed their trust in Oxbryta deserved better. If you or a family member was harmed by this recalled medication, Beverly Wilshire Law APC can help you explore your options. Call (310) 424-5566 or email info@bevwilshire.com for a consultation—we’re here to guide you in the right direction.